Case Report: Gemcitabine Intravesical Hyperthermic Infusion Combined with Tislelizumab in Muscle Invasive Bladder Urothelium Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 9

PMID 36620538

Authors

Zheng Du

Huaqi Yin

Shiming Zhao

Yongkang Ma

Zhenghui Sun

Bingqi Dong

Mingkai Zhu

ChaoShuai Zhu

Jiangshan Peng

Tiejun Yang

Affiliations

Soon will be listed here.

Abstract

Background: Muscle invasive bladder urothelium carcinoma is a common urinary tract tumor. With the deepening of research, more and more treatment methods are applied in clinical practice, extending the life of patients. Among them, the clinical application of chemotherapeutic intravesical hyperthermia and tumor immunotherapy provides new ideas for our treatment.

Case Report: An 81-year-old female patient was diagnosed with stage T2N0M0 bladder cancer in our hospital. Because the patient and her family were keen to preserve her bladder, they declined surgery and opted for combined chemotherapy. After informed consent from the patient and her family, she received cisplatin combined with gemcitabine intravesical hyperthermic infusion. But the side effects of cisplatin made her intolerable to chemotherapy. With their informed consent we changed her to intravenous tislelizumab in combination with gemcitabine intravesical hyperthermic infusion to continue her treatment. During the subsequent follow-up visits, we found a surprising effect of the treatment.

Conclusion: Gemcitabine intravesical hyperthermia therapy combined with intravenous tislelizumab in the treatment of muscle invasive bladder urothelium carcinoma may provide a new possible therapeutic strategy of some patients who are inoperable or refuse surgery.

Citing Articles

Perfusion drugs for non‑muscle invasive bladder cancer (Review).

Qian J, Zhang Q, Cao Y, Chu X, Gao Y, Xu H Oncol Lett. 2024; 27(6):267.

PMID: 38659423 PMC: 11040539. DOI: 10.3892/ol.2024.14400.

References

Rouanne M, Bajorin D, Hannan R, Galsky M, Williams S, Necchi A . Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol. 2020; 3(6):728-738. DOI: 10.1016/j.euo.2020.06.009. View

Lammers R, Witjes J, Inman B, Leibovitch I, Laufer M, Nativ O . The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011; 60(1):81-93. DOI: 10.1016/j.eururo.2011.04.023. View

Schaaf L, Schwab M, Ulmer C, Heine S, Murdter T, Schmid J . Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Res. 2016; 76(10):2868-75. DOI: 10.1158/0008-5472.CAN-15-2908. View

Datta N, Stutz E, Puric E, Eberle B, Meister A, Marder D . A Pilot Study of Radiotherapy and Local Hyperthermia in Elderly Patients With Muscle-Invasive Bladder Cancers Unfit for Definitive Surgery or Chemoradiotherapy. Front Oncol. 2019; 9:889. PMC: 6746906. DOI: 10.3389/fonc.2019.00889. View

Tambyah P, Oon J . Catheter-associated urinary tract infection. Curr Opin Infect Dis. 2012; 25(4):365-70. DOI: 10.1097/QCO.0b013e32835565cc. View

Chen T, Guo J, Han C, Yang M, Cao X . Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009; 182(3):1449-59. DOI: 10.4049/jimmunol.182.3.1449. View

Tan W, Kelly J . Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018; 15(11):667-685. DOI: 10.1038/s41585-018-0092-z. View

Hartmann J, Lipp H . Toxicity of platinum compounds. Expert Opin Pharmacother. 2003; 4(6):889-901. DOI: 10.1517/14656566.4.6.889. View

van der Heijden A, Verhaegh G, Jansen C, Schalken J, Witjes J . Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005; 173(4):1375-80. DOI: 10.1097/01.ju.0000146274.85012.e1. View

10.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

11.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

12.

Palapattu G, Haisfield-Wolfe M, Walker J, BrintzenhofeSzoc K, Trock B, Zabora J . Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol. 2004; 172(5 Pt 1):1814-7. DOI: 10.1097/01.ju.0000141245.08456.1a. View

13.

Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C . Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 2020; 112(1):305-313. PMC: 7780053. DOI: 10.1111/cas.14681. View

14.

Carando R, Pradere B, Afferi L, Marra G, Aziz A, Roghmann F . The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review. Prog Urol. 2020; 30(6):322-331. DOI: 10.1016/j.purol.2020.03.005. View

15.

Lee A, Keam S . Tislelizumab: First Approval. Drugs. 2020; 80(6):617-624. DOI: 10.1007/s40265-020-01286-z. View

16.

Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M . Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021; 13(1). PMC: 7795541. DOI: 10.3390/cancers13010131. View

17.

Issels R, Lindner L, Verweij J, Wessalowski R, Reichardt P, Wust P . Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018; 4(4):483-492. PMC: 5885262. DOI: 10.1001/jamaoncol.2017.4996. View

18.

van der Zee J . Heating the patient: a promising approach?. Ann Oncol. 2002; 13(8):1173-84. DOI: 10.1093/annonc/mdf280. View

19.

Schlack K, Boegemann M, Steinestel J, Schrader A, Krabbe L . The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Rev Anticancer Ther. 2016; 16(3):255-71. DOI: 10.1586/14737140.2016.1143777. View

20.

Kolosnjaj-Tabi J, Marangon I, Nicolas-Boluda A, Silva A, Gazeau F . Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix. Pharmacol Res. 2017; 126:123-137. DOI: 10.1016/j.phrs.2017.07.010. View